Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response
Introduction Major depressive disorder is highly prevalent worldwide and has been affecting an increasing number of people each year. Current first line antidepressants show merely 37% remission, and physicians are forced to use a trial-and-error approach when choosing a single antidepressant out...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2021-04-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821003928/type/journal_article |
| _version_ | 1797616754648678400 |
|---|---|
| author | Y. Avior S. Ron D. Kroitorou E. Nitzan B. Corneo D. Laifenfeld T. Cohen Solal |
| author_facet | Y. Avior S. Ron D. Kroitorou E. Nitzan B. Corneo D. Laifenfeld T. Cohen Solal |
| author_sort | Y. Avior |
| collection | DOAJ |
| description |
Introduction
Major depressive disorder is highly prevalent worldwide and has been affecting an increasing number of people each year. Current first line antidepressants show merely 37% remission, and physicians are forced to use a trial-and-error approach when choosing a single antidepressant out of dozens of available medications.
Objectives
We sought to identify a method of testing that would provide patient-specific information on whether a patient will respond to a medication using in vitro modeling.
Methods
Patient-derived lymphoblastoid cell lines from the STAR*D study were used to rapidly generate cortical neurons and screen them for bupropion effects, for which the donor patients showed remission or non-remission.
Results
We provide evidence for biomarkers specific for bupropion response, including synaptic connectivity and morphology changes as well as specific gene expression alterations.
Conclusions
These biomarkers support the concept of personalized antidepressant treatment based on in vitro platforms and could be utilized as predictors to patient response in the clinic.
Disclosure
This work was funded by Genetika+ Ltd, Jerusalem, Israel. YA, DK, EN, DL and TCS are employees of Genetika+ Ltd and received salary and/or stock options for the submitted work.
|
| first_indexed | 2024-03-11T07:45:45Z |
| format | Article |
| id | doaj.art-f5ca1af7e9834479887ee8aca9d57682 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:45:45Z |
| publishDate | 2021-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-f5ca1af7e9834479887ee8aca9d576822023-11-17T05:07:47ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S143S14310.1192/j.eurpsy.2021.392Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant responseY. Avior0S. Ron1D. Kroitorou2E. Nitzan3B. Corneo4D. Laifenfeld5T. Cohen Solal6R&d, Genetika+, Jerusalem, IsraelR&d, Genetika+, Jerusalem, IsraelR&d, Genetika+, Jerusalem, IsraelR&d, Genetika+, Jerusalem, IsraelStem Cell Core Facility, Columbia University, New York City, United States of AmericaR&d, Genetika+, Jerusalem, IsraelR&d, Genetika+, Jerusalem, Israel Introduction Major depressive disorder is highly prevalent worldwide and has been affecting an increasing number of people each year. Current first line antidepressants show merely 37% remission, and physicians are forced to use a trial-and-error approach when choosing a single antidepressant out of dozens of available medications. Objectives We sought to identify a method of testing that would provide patient-specific information on whether a patient will respond to a medication using in vitro modeling. Methods Patient-derived lymphoblastoid cell lines from the STAR*D study were used to rapidly generate cortical neurons and screen them for bupropion effects, for which the donor patients showed remission or non-remission. Results We provide evidence for biomarkers specific for bupropion response, including synaptic connectivity and morphology changes as well as specific gene expression alterations. Conclusions These biomarkers support the concept of personalized antidepressant treatment based on in vitro platforms and could be utilized as predictors to patient response in the clinic. Disclosure This work was funded by Genetika+ Ltd, Jerusalem, Israel. YA, DK, EN, DL and TCS are employees of Genetika+ Ltd and received salary and/or stock options for the submitted work. https://www.cambridge.org/core/product/identifier/S0924933821003928/type/journal_articleDepressionpersonalized medicinebiomarkersdisease models |
| spellingShingle | Y. Avior S. Ron D. Kroitorou E. Nitzan B. Corneo D. Laifenfeld T. Cohen Solal Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response European Psychiatry Depression personalized medicine biomarkers disease models |
| title | Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response |
| title_full | Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response |
| title_fullStr | Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response |
| title_full_unstemmed | Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response |
| title_short | Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response |
| title_sort | depression patient derived cortical neurons reveal potential biomarkers for antidepressant response |
| topic | Depression personalized medicine biomarkers disease models |
| url | https://www.cambridge.org/core/product/identifier/S0924933821003928/type/journal_article |
| work_keys_str_mv | AT yavior depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT sron depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT dkroitorou depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT enitzan depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT bcorneo depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT dlaifenfeld depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse AT tcohensolal depressionpatientderivedcorticalneuronsrevealpotentialbiomarkersforantidepressantresponse |